These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 34991998)

  • 1. Neglected geriatric assessment and overtreatment of older patients with pancreatic cancer - Results from a prospective phase IV clinical trial.
    Betge J; Schulte N; Belle S; Zhan T; Krammer-Steiner B; Moulin JC; Kleiß M; Lammert F; Wedding U; Räth S; Maenz M; Hegele L; Larcher-Senn J; Jesenofsky R; Ebert MP; Härtel N
    J Geriatr Oncol; 2022 Jun; 13(5):662-666. PubMed ID: 34991998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/- nab-paclitaxel in elderly pancreatic cancer patients (GrantPax).
    Betge J; Chi-Kern J; Schulte N; Belle S; Gutting T; Burgermeister E; Jesenofsky R; Maenz M; Wedding U; Ebert MP; Haertel N
    BMC Cancer; 2018 Jul; 18(1):747. PubMed ID: 30021548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study.
    Yalcin S; Dane F; Oksuzoglu B; Ozdemir NY; Isikdogan A; Ozkan M; Demirag GG; Coskun HS; Karabulut B; Evrensel T; Ustaoglu MA; Ozdemir F; Turna H; Yavuzsen T; Aykan F; Sevinc A; Akbulut H; Yuce D; Hayran M; Kilickap S
    BMC Cancer; 2020 Mar; 20(1):259. PubMed ID: 32228512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry.
    Al-Batran SE; Hofheinz RD; Reichart A; Pauligk C; Schönherr C; Schlag R; Siegler G; Dörfel S; Koenigsmann M; Zahn MO; Schubert J; Aldaoud A; Höffkes HG; Schulz H; Hahn L; Uhlig J; Blau W; Stauch M; Weniger J; Wolf M; Jacobasch L; Bildat S; Wehmeyer J; Homann N; Trojan J; Waidmann O; Fietz T; Feustel HP; Groschek M; Wierecky J; Waibel K; Mahlmann S; Schwindel U; Peters U; Schuch G; Pink D; Eschenburg H; Wörns MA; Harich HD; von Weikersthal LF; Däßler KU; Behringer DM; Messmann H; Kretzschmar A; Gallmeier E; Forstbauer H; Kunzmann V; Papke J; Büchner-Steudel P; Vehling-Kaiser U; Springfeld C; Vogel A; Ettrich TJ; Schaaf M; Hausen GZ; Götze TO;
    Int J Cancer; 2021 Mar; 148(6):1478-1488. PubMed ID: 33038277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study.
    Musher BL; Rowinsky EK; Smaglo BG; Abidi W; Othman M; Patel K; Jawaid S; Jing J; Brisco A; Leen AM; Wu M; Sandin LC; Wenthe J; Eriksson E; Ullenhag GJ; Grilley B; Leja-Jarblad J; Hilsenbeck SG; Brenner MK; Loskog ASI
    Lancet Oncol; 2024 Apr; 25(4):488-500. PubMed ID: 38547893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defining a new treatment option for older vulnerable patients.
    Dotan E; Catalano P; Lenchik L; Boutin R; Yao X; Marques HS; Ioffe D; Zhen DB; Li D; Wagner LI; Simon MA; Wong TZ; O'Dwyer PJ
    J Geriatr Oncol; 2023 Apr; 14(3):101474. PubMed ID: 36963200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Prognostic Utility of a Geriatric Assessment for Patients with Pancreatic Cancer Receiving Gemcitabine-based Chemotherapy: A Prospective Observational Study.
    Kitamura H; Nakazawa J; Nagashima F; Andou M; Furuse J
    Intern Med; 2023 Jun; 62(11):1573-1580. PubMed ID: 36223928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01).
    Rasmussen LS; Winther SB; Chen IM; Weber B; Ventzel L; Liposits G; Johansen JS; Detlefsen S; Egendal I; Shim S; Christensen S; Pfeiffer P; Ladekarl M
    BMC Cancer; 2023 Jun; 23(1):552. PubMed ID: 37328835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer.
    Kobayashi S; Suzuki M; Ueno M; Maruki Y; Okano N; Todaka A; Ozaka M; Tsuji K; Shioji K; Doi K; Kojima Y; Tsumura H; Tanaka K; Higuchi H; Kawabe K; Imaoka H; Yamashita T; Miwa H; Nagano H; Arima S; Hayashi H; Naganuma A; Yamaguchi H; Hisano T; Umemoto K; Ishii S; Nakashima K; Suzuki R; Kitano Y; Misumi T; Furuse J; Ishii H
    Oncologist; 2022 Oct; 27(10):e774-e782. PubMed ID: 35946841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
    Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
    BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma.
    Babiker H; Schlegel PJ; Hicks LG; Bullock AJ; Burhani N; Mahadevan D; Elquza E; Borad MJ; Benaim E; Peterson C; Heaton C; Ocean AJ
    Invest New Drugs; 2022 Feb; 40(1):81-90. PubMed ID: 34417914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
    Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
    BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients.
    Yang SH; Guo JC; Hsu C; Kuo SH; Tien YW; Cheng AL; Yeh KH
    J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):97-105. PubMed ID: 30852003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial.
    Bekaii-Saab T; Okusaka T; Goldstein D; Oh DY; Ueno M; Ioka T; Fang W; Anderson EC; Noel MS; Reni M; Choi HJ; Goldberg JS; Oh SC; Li CP; Tabernero J; Li J; Foos E; Oh C; Van Cutsem E
    EClinicalMedicine; 2023 Apr; 58():101897. PubMed ID: 36969338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential Geriatric Assessment in Older Patients with Colorectal Cancer during Chemotherapy: Subgroup Analysis of a Prospective, Multicenter Study EpiReal 75.
    Li M; Schulte N; Elting F; Winkler EC; Hetjens S; Berger AK; Zschäbitz S; Hofmann J; Hofmann J; Hilbertz L; Kuhn M; Khakzar C; Jesenofsky R; Betge J; Zhan T; Belle S; Ebert MP; Härtel N
    Oncol Res Treat; 2022; 45(11):670-680. PubMed ID: 35675788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer.
    Bodeker KL; Smith BJ; Berg DJ; Chandrasekharan C; Sharif S; Fei N; Vollstedt S; Brown H; Chandler M; Lorack A; McMichael S; Wulfekuhle J; Wagner BA; Buettner GR; Allen BG; Caster JM; Dion B; Kamgar M; Buatti JM; Cullen JJ
    Redox Biol; 2024 Nov; 77():103375. PubMed ID: 39369582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Interactions Causing Warfarin Overdose in a Patient with Pancreatic Cancer: A Case Report.
    Moussouni M; Graff V; Couturier F; Herrscher H
    Chemotherapy; 2023; 68(2):111-114. PubMed ID: 36446317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1 blockade combined with gemcitabine plus nab-paclitaxel is superior to chemotherapy alone in the management of unresectable stage III/IV pancreatic cancer: a retrospective real-world study.
    Cheng D; Hu J; Wu X; Wang B; Chen R; Zhao W; Fang C; Ji M
    Front Oncol; 2023; 13():1281545. PubMed ID: 37965469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of comprehensive geriatric assessment on care received, treatment completion, toxicity, cancer-related and geriatric assessment outcomes, and quality of life for older adults receiving systemic anti-cancer treatment: A systematic review.
    Disalvo D; Moth E; Soo WK; Garcia MV; Blinman P; Steer C; Amgarth-Duff I; Power J; Phillips J; Agar M
    J Geriatr Oncol; 2023 Nov; 14(8):101585. PubMed ID: 37573197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective clinical trial evaluating vulnerability and chemotherapy risk using geriatric assessment tools in older patients with lung cancer.
    Tsubata Y; Shiratsuki Y; Okuno T; Tanino A; Nakao M; Amano Y; Hotta T; Hamaguchi M; Okimoto T; Hamaguchi S; Kurimoto N; Nishiyama Y; Kimura T; Iwata H; Tsumoto S; Isobe T
    Geriatr Gerontol Int; 2019 Nov; 19(11):1108-1111. PubMed ID: 31746525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.